Under a tenth of people who could benefit from weight-loss injections like Wegovy can access them, warns the global health agency as it publishes its inaugural guidance on the drugs.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is calling for broader and more equitable availability to GLP-1 medication.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our latest guidance affirms that excess weight is a chronic disease that can be treated with thorough and lifelong support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are key obstacles to widespread access to the treatments that can help people shift considerable weight, explains the body.
Skinny Jab Supply Crisis
Even in the present most optimistic outlook, the manufacturing of such drugs might only reach around 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The recommendation calls on governments and firms to increase availability, via strategies like voluntary licensing.
A patent on semaglutide – the main component of a leading brand – is due to expire in several nations in 2026.
How Obesity Injections Operate
GLP-1 drugs replicate a natural hormone to slow digestion, curb appetite and enhance satiety so users consume fewer calories.
People typically begin shedding pounds in the initial weeks of commencing the weekly injections.
Evidence suggests people may regain a significant portion after a year of stopping the treatment, when their usual appetite come back.
Being carrying excess weight elevates your likelihood for experiencing health problems, like type 2 diabetes, heart disease, stroke, and specific cancers.
Obesity concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the health agency.
